相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2001
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- AGC Biologics has signed a long-term strategic manufacturing agreement with an undisclosed major biopharmaceutical company, with total order value expected to reach several hundred million dollars. - The contract covers commercial production of five biologic drugs, committing to a minimum of 35 batches per year utilizing half of the Yokohama site's mammalian manufacturing capacity. - The new Yokohama facility, slated to begin GMP-compliant services in 2027, will feature 18,000 liters of single-use bioreactor capacity alongside mRNA and cell therapy capabilities. - The agreement signals growing industry demand for geopolitically stable supply chains, positioning Japan as a trusted hub for global biopharmaceutical manufacturing.
- AGC Biologics has been selected by Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 therapy targeting lumbar disc herniation. - The partnership leverages AGC Biologics' global network with initial cell bank creation in Heidelberg, Germany, followed by process development and GMP manufacturing in Chiba, Japan for clinical trials. - This collaboration highlights AGC Biologics' unique position as the only CDMO offering microbial manufacturing across three continents, providing supply chain security and flexibility for drug developers. - The therapy represents a potentially less invasive treatment option for patients suffering from lumbar disc herniation, addressing an important unmet medical need.
- Novelty Nobility expanded its manufacturing agreement with AGC Biologics to advance bispecific antibody NN4101 through GMP manufacturing at the Chiba, Japan facility. - NN4101 is a first-in-class bispecific antibody combining anti-c-Kit monoclonal antibody with VEGF trap for treating neovascular retinal diseases. - The partnership leverages AGC Biologics' global network, with cell line development completed in Copenhagen and tech transfer proceeding to Chiba for critical manufacturing stages. - AGC Biologics is expanding its Japan footprint with a new Yokohama facility featuring advanced single-use bioreactor technology for large-scale GMP manufacturing.
- Pandorum Technologies raised $18 million in Series B funding led by Protons Corporate to advance clinical development of its programmable exosome-based regenerative therapies. - The company's lead therapy Kuragenx has received FDA Orphan Drug Designation for treating rare ocular surface diseases including Stevens-Johnson Syndrome and Neurotrophic Keratitis. - Funding will support global manufacturing scale-up through partnerships with AGC Biologics and Nucelion Therapeutics, while expanding operations across the US, Japan, and Middle East markets.
- AGC Biologics' Seattle facility received Good Manufacturing Practices certification from Brazil's Anvisa, enabling biologics and biosimilars produced at the site to be commercialized in South America's largest pharmaceutical market. - The certification extends global reach for AGC Biologics customers into Brazil's $40 billion pharmaceutical market, which is projected to grow to nearly $74 billion by 2032. - The Seattle site is now cGMP-certified in 11 different countries and achieved a 100% batch success rate in 2025, demonstrating robust international manufacturing capabilities. - This marks the second AGC Biologics facility to receive Anvisa GMP certification, following the Copenhagen site's approval in 2023, facilitating potential tech transfers between locations.
- The global nucleic acid therapeutics contract manufacturing market is projected to grow from $9.85 billion in 2024 to $33.84 billion by 2033, representing a CAGR of 15.14%. - Record-high outsourcing levels drive market expansion, with 82.6% of cell and gene therapy companies now outsourcing at least part of their biologics manufacturing. - Rising demand for mRNA and gene therapies, combined with technological manufacturing advancements and regulatory support, fuels the market's rapid growth trajectory.
- The global cell and gene therapy market is expected to exceed $105 billion by 2033, driven by significant expansion in clinical pipelines with Phase I trials experiencing approximately 11% growth. - Cell therapy dominates the market with 61.2% share, reaching $14.66 billion in 2023, while manufacturing costs remain a challenge with CAR-T therapies exceeding $100,000 per patient. - North America leads the market with 43.7% share at $11.97 billion in 2023, supported by advanced regulatory frameworks including the FDA's RMAT designation for accelerated therapy review. - Advanced delivery vectors and viral vector platforms are driving innovation, with companies like AGC Biologics and Charles River Laboratories launching new manufacturing solutions to improve scalability and reduce costs.
- AGC Biologics announced a partnership with Repair Biotechnologies on November 19, 2025, to develop and manufacture a novel mRNA therapy targeting atherosclerotic plaques, which are a leading cause of heart attacks and strokes globally. - This collaboration represents a significant expansion of mRNA technology applications beyond infectious diseases into chronic cardiovascular disease treatment, leveraging AGC's established expertise in mRNA manufacturing. - The partnership highlights AGC's strategic shift to diversify its Life Science segment and transition from persistent losses to potential growth, while the company continues to face challenges in its core glass and chemicals markets. - AGC's stock has shown positive momentum with an 18.7% total shareholder return over the past year, reflecting investor optimism about the company's biotech capabilities and strategic partnerships.
- The U.S. cell and gene therapy CDMO market is projected to grow from $1.94 billion in 2025 to $10.34 billion by 2033, representing a robust 23.26% compound annual growth rate. - Recent FDA approvals of breakthrough therapies including Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy are driving increased demand for specialized manufacturing partnerships. - Over 2,000 ongoing clinical trials in cell and gene therapies are creating unprecedented demand for viral vectors, plasmids, and clinical-grade cell processing capabilities. - Leading CDMO players including Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher are investing heavily in expanding manufacturing capacity to meet surging outsourcing demand.
- AGC Biologics has partnered with Repair Biotechnologies to develop and manufacture a novel mRNA therapy targeting atherosclerotic plaques, which cause 27% of all human mortality. - The collaboration leverages AGC Biologics' comprehensive mRNA manufacturing capabilities to provide a streamlined path from preclinical development to clinical trials. - Repair Biotechnologies is developing a first-in-class therapy that breaks down toxic free cholesterol inside cells to rapidly reduce arterial plaque and reverse cardiovascular conditions. - This partnership represents the evolution of mRNA technology beyond infectious diseases into treating chronic, age-related conditions affecting cardiovascular health.
